Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Session Type:

Availability:

Showing session: reset

Antivirals For HIV, MPXV, and SARS-CoV-2: New Drug Strategies and Resistance

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 13 of 13
Introduction of Speakers Part 1
from CROI 2025 on March 11, 2025 10:00 AM-12:00 PM
Efficacy and Safety of Lenacapavir, Teropavimab, and Zinlirvimab: Phase II Week 26 Primary Outcome   (ABSTRACT 151)
Onyema Ogbuagu
Yale University, New Haven, CT, USA
from CROI 2025 on March 11, 2025 10:00 AM-12:00 PM
Proof-of-Concept Trial of VH4524184 (VH-184), a Third-Generation Integrase Strand Transfer Inhibitor   (ABSTRACT 152)
Luise Rogg
ViiV Healthcare, Durham, NC, USA
from CROI 2025 on March 11, 2025 10:00 AM-12:00 PM
Proof-of-Concept Trial of Oral VH4011499 (VH-499), a New HIV-1 Capsid Inhibitor   (ABSTRACT 153)
Paul Benn
ViiV Healthcare, Brentford, UK
from CROI 2025 on March 11, 2025 10:00 AM-12:00 PM
Pharmacokinetics and Safety of Once-Yearly Formulations of Lenacapavir   (ABSTRACT 154)
Renu Singh
Gilead Sciences, Inc, Foster City, CA, USA
from CROI 2025 on March 11, 2025 10:00 AM-12:00 PM
Questions and Answers Part 1
from CROI 2025 on March 11, 2025 10:00 AM-12:00 PM
Introduction of Speakers Part 2
from CROI 2025 on March 11, 2025 10:00 AM-12:00 PM
Elucidating the Mechanism by Which Nucleocapsid Mutations Confer Resistance to InSTIs   (ABSTRACT 155)
Yuta Hikichi
National Cancer Institute at Frederick, Frederick, MD, USA
from CROI 2025 on March 11, 2025 10:00 AM-12:00 PM
Selection of Nucleocapsid Mutations With Virologic Failure of Tenofovir/Lamivudine/Dolutegravir   (ABSTRACT 156)
Kerri J. Penrose
University of Pittsburgh, Pittsburgh, PA, USA
from CROI 2025 on March 11, 2025 10:00 AM-12:00 PM
Optimizing On-Demand Tenofovir Disoproxil Fumarate/Emtricitabine Dosing in Women for HIV Prevention   (ABSTRACT 157)
Mackenzie Cottrell
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
from CROI 2025 on March 11, 2025 10:00 AM-12:00 PM
Safety and Antiviral Efficacy of a Broad-Spectrum siRNA SNS812 Targeting SARS-CoV-2: Phase II Trial   (ABSTRACT 158)
Shey-Ying Chen
National Taiwan University Hospital, Taipei, Taiwan
from CROI 2025 on March 11, 2025 10:00 AM-12:00 PM
Host and Disease Factors Were Not Associated With Mpox Resolution in Participants Receiving Tpoxx   (ABSTRACT 159)
William A. Fischer II
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
from CROI 2025 on March 11, 2025 10:00 AM-12:00 PM
Questions and Answers Part 2
from CROI 2025 on March 11, 2025 10:00 AM-12:00 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 13 of 13